Tazverik Dosage
Generic name: tazemetostat hydrobromide 200mg
Dosage form: tablet, film coated
Drug class: Miscellaneous antineoplastics
Medically reviewed by Drugs.com. Last updated on Aug 15, 2024.
Patient Selection
Select patients with R/R FL for treatment with TAZVERIK based on the presence of EZH2 mutation of codons Y646, A682, or A692 in tumor specimens. Information on FDA-approved tests for the detection of EZH2 mutation in relapsed or refractory follicular lymphoma is available at: http://www.fda.gov/CompanionDiagnostics.
Recommended Dosage
The recommended dosage of TAZVERIK is 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity.
Swallow tablets whole. Do not cut, crush, or chew tablets.
Do not take an additional dose if a dose is missed or vomiting occurs after TAZVERIK, but continue with the next scheduled dose.
Dosage Modifications for Adverse Reactions
Table 1 summarizes the recommended dose reductions, and Table 2 summarizes the recommended dosage modifications of TAZVERIK for adverse reactions.
*Permanently discontinue TAZVERIK in patients who are unable to tolerate 400 mg orally twice daily. |
|
Dose Reduction | Dosage |
First | 600 mg orally twice daily |
Second | 400 mg orally twice daily* |
Adverse Reaction | Severity | Dosage Modification |
---|---|---|
Neutropenia |
Neutrophil count less than 1 × 109/L |
|
Thrombocytopenia |
Platelet count less than 50 × 109/L |
|
Anemia |
Hemoglobin less than 8 g/dL |
|
Other adverse reactions |
Grade 3 |
|
Grade 4 |
|
Dosage Modifications for Drug Interactions
Strong or Moderate CYP3A Inhibitors
Avoid coadministration of TAZVERIK with strong or moderate CYP3A inhibitors. If coadministration with a strong or moderate CYP3A inhibitor cannot be avoided, reduce the TAZVERIK dose as shown in Table 3 below. After discontinuation of the strong or moderate CYP3A inhibitor for 3 elimination half-lives, resume the TAZVERIK dose that was taken prior to initiating the inhibitor.
Current Dosage | Adjusted Dosage |
800 mg orally twice daily | 400 mg orally twice daily |
600 mg orally twice daily | 400 mg for first dose and 200 mg for second dose |
400 mg orally twice daily | 200 mg orally twice daily |
More about Tazverik (tazemetostat)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi (tafasitamab-cxix) is used for the treatment of relapsed or refractory diffuse large B-cell ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma, two types of non-Hodgkin ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Lunsumio
Lunsumio (mosunetuzumab-axgb) is used for the treatment of relapsed or refractory follicular ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.